You might like
BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”
Dr Rahul Banerjee (@RahulBanerjeeMD) of @fredhutch shares his favorite presentations from #IMS25 and explains why he finds them interesting. #IMS2025 #mmsm Read more here: shorturl.at/xaGmE
Well-deserved @MHajiyianni & @HDMyeloma 🙌 #mmsm
At #IMS25, @MHajiyianni, of @uniklinik_hd, presented the results of an imaging sub-study from the phase 3 GMMG-HD7 clinical trial of isatuximab combined with bortezomib, lenalidomide, and dexamethasone for #myeloma. 📖 Read more: buff.ly/2dkShGo
1st results of the #GMMGHD7 imaging substudy presented at #IMS2025 ➡️ lower WB-MRI (MY-RADS) scores correlate with MRD negativity after induction in #mmsm Congrats to @MHajiyianni on receiving the Young Investigator Award for these great work! 👏
Exciting data from MajesTEC-5 by Dr. Raab. Tec-Dara based induction leading to ~100% MRD-negativity rate by NGS at 10^-6 post Cycle#6. At ~7 mo f/u risk of Grade 3 or higher infection ~37% (no deaths from infection yet). My thoughts: Is ASCT necessary with such deep response…
And #IMS25 @RaabMarc adding that they even switched from NGF to NGS at 10^-6 to be sure... still 100% MRD neg across the board. Truly remains the best induction data in #MMsm the world has ever seen... and my guess is that IVIG is helping to lower AE profile substantially!
But perhaps the BIGGEST change that will affect my interpretation of trials is new neutropenia cutoffs! v5 = Gr1 is LLN to 1500, Gr2 is 1000-1500, Gr3 is 500-1000, Gr4 is <500... Now in v6 = Gr1 is 1000-1500, Gr2 is 500-1000, Gr3 is 100-500, Gr4 is <100!!!
1/ New @BloodAdvances treasure trove of 🇩🇪 🇺🇸 data about bridging before CAR-T in #MMsm. Bigger is not better when it comes to bridging using chemotherapy... Worse post-CAR-T efficacy (unsurprising: tumor biology as confounder) but also clearly worse cytopenias & infections!
🚨 NEWS 🚨 @EU_Commission has approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) for the treatment of transplant-eligible newly diagnosed #MultipleMyeloma, based on data from the phase III GMMG-HD7 trial. Learn more:…
Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm nature.com/articles/s4157… @EHA_Hematology @EMN_EuMMnet @UoATherapeutics
The paper of the day: a landmark publication that is bound to serve as a reference for years to come! @NatRevClinOncol @thanosdimop @COMyCongress @TheIACH @mbeksac56
On being a good doctor. The number of research publications don’t tell you how good a doctor is at being a doctor. Neither do the number of book chapters or grants. Or academic rank. It’s a different skill set. Good doctors have stellar clinical acumen & empathy. #MedTwitter
On being a good doctor Part II (after being on the other side as a patient advocate) - Understand the patient and the clinical problem they face. It is more than just analyzing lab results and scans. 90% of diagnosis is history. - History taking/acquisition is a skill.…
Looking forward to speaking on treatment of High-risk #myeloma at @EHA_Hematology conference in Milano in June - many thanks @Myeloma_Society and EHA for invite. In the meantime, hope people might enjoy our @BritSocHaem podcast on this topic: podbean.com/ew/pb-2734e-17…
podbean.com
Podbean Podcast App & Player
Diagnosis and initial treatment of transplant-eligible high-risk...
Beth Jacobson reached out to Dr. Folkman upon Dr. Bergsagel’s suggestion. Dr. Folkman mentioned his idea of using thalidomide to treat cancer. She felt thalidomide can work for myeloma and mentioned it to Dr. Bart Barlogie at University of Arkansas who was treating her husband.…
'Less is more' maintenance therapy in #MultipleMyeloma! Triplets→ASCT→3yr Len → D/C if MRD-neg (NGF+PET/CT-neg) Results: 3yr PFS ~93%, TFS ~75% *Treatment initiated for MRD resurgence Based on @bdermanmd 's MRD2STOP + this data: I'm comfortable stopping Len in standard-risk…
Now in @BloodJournal: congrats @thanosdimop et al on studying this prospectively! I love the abstract! Stopping len is a burning question for the #MMsm community and can also stop burning holes in our pocketbooks 💸 Good to see such great post-discontinuation PFS data here!
United States Trends
- 1. TOP CALL 3,843 posts
- 2. Good Monday 26.6K posts
- 3. AI Alert 1,384 posts
- 4. #BaddiesUSA 65.5K posts
- 5. #centralwOrldXmasXFreenBecky 528K posts
- 6. SAROCHA REBECCA DISNEY AT CTW 548K posts
- 7. NAMJOON 53.8K posts
- 8. #LingOrmDiorAmbassador 283K posts
- 9. #MondayMotivation 7,277 posts
- 10. Check Analyze N/A
- 11. Token Signal 1,836 posts
- 12. Market Focus 2,550 posts
- 13. Rams 30.4K posts
- 14. #LAShortnSweet 24.5K posts
- 15. Vin Diesel 1,560 posts
- 16. DOGE 182K posts
- 17. Scotty 10.5K posts
- 18. Chip Kelly 9,222 posts
- 19. Stacey 24.4K posts
- 20. Ahna 7,931 posts
Something went wrong.
Something went wrong.